enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA approves new type of schizophrenia drug - AOL

   www.aol.com/news/fda-approves-type-schizophrenia...

   The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...

3. FDA Approves the First New Schizophrenia Drug in Decades - AOL

   www.aol.com/fda-approves-first-schizophrenia...

   N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...

4. Neurocrine halts development of schizophrenia drug as ... - AOL

   www.aol.com/news/neurocrine-halts-development...

   In the previous study, luvadaxistat failed to meet the main goal of change from baseline in negative symptoms of schizophrenia, however, it met the secondary goal of improving cognitive performance.

5. Brilaroxazine - Wikipedia

   en.wikipedia.org/wiki/Brilaroxazine

   RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...

6. Schizophrenia In America - The Huffington Post

   highline.huffingtonpost.com/articles/en/stop-the...

   It was through her work that, in the early 2000s, she heard about a radical new approach to schizophrenia that had been developed by researchers in Australia. Tamara was shocked to discover that this program took a very different attitude toward schizophrenia than nearly everyone who had treated her brother.

7. Stanley Center for Psychiatric Research at Broad Institute

   en.wikipedia.org/wiki/Stanley_Center_for...

   In July 2014, the Broad Institute announced that Ted Stanley had committed an additional $650 million to the center. [6] The commitment – the largest ever made for psychiatric research—was aimed at "enhancing scientific research on psychiatric disorders with the hopes of leading to a breakthrough in new treatments." [7]